NZ703152A - Dosing regimen for janus kinase (jak) inhibitors - Google Patents

Dosing regimen for janus kinase (jak) inhibitors

Info

Publication number
NZ703152A
NZ703152A NZ703152A NZ70315213A NZ703152A NZ 703152 A NZ703152 A NZ 703152A NZ 703152 A NZ703152 A NZ 703152A NZ 70315213 A NZ70315213 A NZ 70315213A NZ 703152 A NZ703152 A NZ 703152A
Authority
NZ
New Zealand
Prior art keywords
jak
janus kinase
inhibitors
dosing regimen
dog
Prior art date
Application number
NZ703152A
Other languages
English (en)
Inventor
Andrea J Gonzales
Sallie B Cosgrove
Phyllis B Malpas
Michael Rolf Stegemann
Wendy Turner Collard
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ703152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of NZ703152A publication Critical patent/NZ703152A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
NZ703152A 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors NZ703152A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (1)

Publication Number Publication Date
NZ703152A true NZ703152A (en) 2016-03-31

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ703152A NZ703152A (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Country Status (25)

Country Link
US (1) US9522151B2 (cg-RX-API-DMAC7.html)
EP (1) EP2874630B1 (cg-RX-API-DMAC7.html)
JP (2) JP6022063B2 (cg-RX-API-DMAC7.html)
KR (2) KR20170034949A (cg-RX-API-DMAC7.html)
CN (2) CN104470525A (cg-RX-API-DMAC7.html)
AU (1) AU2013292547B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015000808A2 (cg-RX-API-DMAC7.html)
CA (1) CA2878867C (cg-RX-API-DMAC7.html)
CY (1) CY1121436T1 (cg-RX-API-DMAC7.html)
DK (1) DK2874630T3 (cg-RX-API-DMAC7.html)
ES (1) ES2707627T3 (cg-RX-API-DMAC7.html)
HK (2) HK1209314A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20182088T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042771T2 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN00370A (cg-RX-API-DMAC7.html)
LT (1) LT2874630T (cg-RX-API-DMAC7.html)
MX (1) MX360857B (cg-RX-API-DMAC7.html)
NZ (1) NZ703152A (cg-RX-API-DMAC7.html)
PL (1) PL2874630T3 (cg-RX-API-DMAC7.html)
PT (1) PT2874630T (cg-RX-API-DMAC7.html)
RS (1) RS58242B1 (cg-RX-API-DMAC7.html)
SI (1) SI2874630T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900044T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014015107A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500134B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3290421T1 (sl) 2013-02-22 2019-03-29 Pfizer Inc. Kombinacija derivatov pirolo (2,3-D)pirimidina z enim ali več dodatnimi sredstvi za zaviranje z janusom povezane kinaze (JAK)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN120478294A (zh) 2015-10-16 2025-08-15 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2017143014A1 (en) 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
CN107098908B (zh) 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
PT3915989T (pt) * 2019-01-30 2023-10-02 Felicamed Biotechnology Co Ltd Inibidor de jak e método de preparação do mesmo
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
MX2023007150A (es) 2020-12-18 2023-09-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
CA3212256A1 (en) * 2021-03-16 2022-09-22 Juhyun Lee Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
EP4327812A4 (en) * 2021-04-22 2025-01-15 Shenzhen Chipscreen Biosciences Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A SELECTIVE JAK3/JAK1/TBK1 INHIBITOR AND ITS MEDICAL USE
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005852B1 (ru) * 1998-06-19 2005-06-30 Пфайзер Продактс Инк. ПИРРОЛО[2,3-d]ПИРИМИДИНЫ
KR101335843B1 (ko) * 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-d]피리미딘 화합물

Also Published As

Publication number Publication date
CY1121436T1 (el) 2020-05-29
HUE042771T2 (hu) 2019-07-29
KR20170034949A (ko) 2017-03-29
EP2874630A1 (en) 2015-05-27
BR112015000808A2 (pt) 2017-06-27
DK2874630T3 (en) 2019-01-28
IN2015DN00370A (cg-RX-API-DMAC7.html) 2015-06-12
PT2874630T (pt) 2019-01-31
JP2017019816A (ja) 2017-01-26
CN108354938A (zh) 2018-08-03
SI2874630T1 (sl) 2019-04-30
MX360857B (es) 2018-11-20
WO2014015107A1 (en) 2014-01-23
AU2013292547A1 (en) 2015-01-22
EP2874630B1 (en) 2018-12-05
RS58242B1 (sr) 2019-03-29
SMT201900044T1 (it) 2019-02-28
US20150126535A1 (en) 2015-05-07
HK1252083A1 (zh) 2019-05-17
JP2015522620A (ja) 2015-08-06
HK1209314A1 (en) 2016-04-01
CA2878867C (en) 2018-01-09
ES2707627T3 (es) 2019-04-04
PL2874630T3 (pl) 2019-04-30
KR20150028299A (ko) 2015-03-13
LT2874630T (lt) 2019-02-11
CA2878867A1 (en) 2014-01-23
JP6022063B2 (ja) 2016-11-09
AU2013292547B2 (en) 2017-05-04
MX2015000871A (es) 2015-05-07
CN104470525A (zh) 2015-03-25
US9522151B2 (en) 2016-12-20
HRP20182088T1 (hr) 2019-02-08
ZA201500134B (en) 2016-08-31

Similar Documents

Publication Publication Date Title
NZ703152A (en) Dosing regimen for janus kinase (jak) inhibitors
MX2013013294A (es) Inhibidores de tirosina-cinasas.
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
PH12013502020A1 (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
GEP201706748B (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
NZ630925A (en) Pyrazolopyrimidine compounds as kinase inhibitors
PH12016500756A1 (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
NZ630457A (en) Compounds useful as inhibitors of atr kinase
EA201690357A1 (ru) Лекарственные формы с замедленным высвобождением для ингибитора jak1
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA201690752A1 (ru) Ингибиторы g12c kras
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
TN2015000368A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
UA115320C2 (uk) Інгібітори кінази
EP4233869A3 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
WO2013052699A3 (en) Novel quinoxaline inhibitors of pi3k
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
AU2013270326B2 (en) Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof
WO2013004995A8 (en) Pyrimidinone compounds and their use

Legal Events

Date Code Title Description
PSEA Patent sealed
ASS Change of ownership

Owner name: ZOETIS SERVICES LLC, US

Effective date: 20161124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2018 BY THOMSON REUTERS

Effective date: 20170621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2019 BY THOMSON REUTERS

Effective date: 20180622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2020 BY THOMSON REUTERS

Effective date: 20190620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2021 BY THOMSON REUTERS

Effective date: 20200622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2022 BY THOMSON REUTERS

Effective date: 20210604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2023 BY THOMSON REUTERS

Effective date: 20220604

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2024 BY THOMSON REUTERS

Effective date: 20230602

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2025 BY THOMSON REUTERS

Effective date: 20240603

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUL 2026 BY THOMSON REUTERS

Effective date: 20250604